Biotechcquisition Company Class A (BIOT) Financials

$0.37

$-9.78 (-96.35%)

As on 11-Sep-2026 09:30EDT

Market cap

$-- Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	3.74	1.57	--	--	--	--
Gross Profit	-3.74	-1.57	--	--	--	--
Operating Expenses	3.74	1.57	--	--	--	--
Operating Profit (EBIT)	-3.74	-1.57	--	--	--	--
Other Income	10.50	-4.80	--	--	--	--
Profit before Tax	8.02	-6.86	--	--	--	--
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	8.04	-6.86	--	--	--	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	8.04	-6.86	-0.02	--	--	--

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	-13.12	0.00	0.02	--	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	9.70	0.00	--	--	--	--
Current Liabilities	3.52	--	0.07	--	--	--
Total Liabilities	12.26	0.00	0.09	--	--	--

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	231.29	0.00	0.09	--	--	--
Current Assets	0.10	--	--	--	--	--
Total Assets	234.91	--	0.09	--	--	--
Total Debt*	--	--	--	--	--	--
Net Current Assets	-3.42	-0.01	--	--	--	--

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-1.47	-1.47	--	--	--
Cash Flow from Investing Activities	--	-230.00	-230.00	--	--	--
Cash from Financing Activities	--	231.56	231.56	--	--	--
Net Cash Inflow / Outflow	--	0.09	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	1.34	-1.14	--	--	--	--
Cash EPS ($)	--	-1.14	--	--	--	--
Adjusted Book Value ($)	--	--	0.00	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.24	-0.29	--	--	--
Free Cash Flow per Share ($)	--	-0.24	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-68,738.61	--	--	--	--
ROE (%)	--	-68,738.61	--	--	--	--
ROA (%)	3.45	-15,300.53	--	--	--	--
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	76.57	143.15	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	--	-42,337.10	--	--	--	--
Net Profit Growth (%)	--	--	--	--	--	--
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	-106.24	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-8.59	--	--	--	--
Price / Book Value	--	-2,184,444.44	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	--	-8.59	--	--	--	--
Close Price ($)	9.92	9.83	--	--	--	--
High Price ($)	10.41	9.95	--	--	--	--
Low Price ($)	8.30	9.54	--	--	--	--
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	3.48	--	--	--
Current Ratio	0.03	--	--	--	--	--
Quick Ratio	0.03	--	--	--	--	--
Interest Coverage	--	--	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	73.00	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.